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Abstract
Seroreactivity profiling emerges as valuable technique for minimal invasive cancer detection. Recently, we provided
first evidence for the applicability of serum profiling of glioma using a limited number of immunogenic antigens. Here,
we screened 57 glioma and 60 healthy sera for autoantibodies against 1827 Escherichia coli expressed clones, includ-
ing 509 in-frame peptide sequences. By a linear support vector machine approach, we calculated mean specificity,
sensitivity, and accuracy of 100 repetitive classifications. We were able to differentiate glioma sera from sera of the
healthy controls with a specificity of 90.28%, a sensitivity of 87.31% and an accuracy of 88.84%. We were also able
to differentiate World Health Organization grade IV glioma sera from healthy sera with a specificity of 98.45%,
a sensitivity of 80.93%, and an accuracy of 92.88%. To rank the antigens according to their information content,
we computed the area under the receiver operator characteristic curve value for each clone. Altogether, we found
46 immunogenic clones including 16 in-frame clones that were informative for the classification of glioma sera
versus healthy sera. For the separation of glioblastoma versus healthy sera, we found 91 informative clones including
26 in-frame clones. The best-suited in-frame clone for the classification glioma sera versus healthy sera corresponded
to the vimentin gene (VIM) that was previously associatedwith glioma. In the future, autoantibody signatures in glioma
not only may prove useful for diagnosis but also offer the prospect for a personalized immune-based therapy.
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Introduction
Gliomas are the most common primary brain tumor with an annual
incidence of approximately 6 in 100,000 persons [1]. Gliomas arise
from the neuroepithelial tissue with the main morphologic subtype of
gliomas being astrocytomas representing 75% of all gliomas, followed
by oligodendrogliomas with 8.4%. The World Health Organization
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(WHO) classifies astrocytomas into four malignancy grades [2]. WHO
grade I or pilocytic astrocytomas comprise 5.8% of all gliomas and are
the most frequent brain tumors in children and adolescents. WHO II
or diffuse astrocytomas account for 1.5% of all gliomas and are char-
acterized by tendencies to recur and to progress to higher-grade astro-
cytomas. WHO III or anaplastic astrocytomas that comprise 7.5%
of gliomas frequently progress after a mean interval of 2 years. Glio-
blastoma multiforme (WHO grade IV) that account for 18.5% of all
primary brain tumors are fast-growing, highly infiltrating tumors with
a mean survival of approximately 1 year after diagnosis.
Treatment of malignant glioma includes maximal surgery followed
by radiotherapy with concomitant and adjuvant temozolomide therapy.
Although recent therapeutic advances have improved standard treat-
ment only few patients experience prolonged survival. New targeted
therapies include infection with a p53-producing adenovirus to re-
establish normal p53 expression in gliomas and lyses of glioma cells
by modified herpes simplex virus. Besides various attempts to targeted
therapy for glioma [3], there are also attempts to use the immune
response for therapeutical purposes including vaccination with an
EGFRvIII peptide or autologous dendritic cells pulsed with glioma
lysate (reviewed in Selznick et al. [4]). One major challenge for glioma
treatment is the tremendous heterogeneity especially of glioblastoma.
An approach to address this challenge is the identification of a large
number of tumor antigens that can be used both for therapy and for
diagnosis. Lately, immunogenic antigens have been combined to define
autoantibody signatures that have been reported for a variety of cancers
including prostate, lung, ovarian, and brain cancers [5–19]. Recently,
we identified 35 antigens that allowed detecting a specific autoantibody
signature of glioma [12]. Glioma sera were separated form control sera
with a specificity of 86.1%, a sensitivity of 85.2%, and an accuracy of
85.8%. Here, we set out to largely extend the number of antigens that
cause an immune response in patients whose conditions were diagnosed
as glioma. In detail, we screened an array encompassing 1827 clones for
reactivity against serum autoantibodies of glioma patients by using a
newly developed image analysis software. We also ask how specific the
new antigens are for gliomas.
Materials and Methods
Patients’ Sera
Blood samples of glioma patients and healthy controls were obtained
from the Departments of Neurosurgery and Hemastaseology of Saarland
University with patients’ informed consent. Serum was isolated from
serum gel monovettes by centrifugation and stored at −70°C. Table 1
provides more detailed information on age and sex of the patients and
control group.
Screening Procedure
We screened high-density protein macroarrays arraying 38,016
Escherichia coli expressed proteins of the hex1 library [20] with 150 sera
of various cancer and non–cancer sera including 30 sera of glioma pa-
tients of all four WHO grades. All clones that were positive in at least
one serum were selected and spotted in duplicates on subarray filters.
These subarrays encompassing 1827 immunoreactive E. coli clones
were then screened with 57 sera of glioma patients and 60 sera of
healthy controls. In brief, filters were washed twice with TBSTT
(TBS, 0.05% Tween 20, and 0.5% Triton X-100) and four times with
TBS and then blocked 2 hours in blocking solution (TBS, 0.05%
Tween 20, and 3% dry milk). Subsequently, membranes were incu-
bated overnight with serum dilution (1:1000 in TBST/3% dry milk).
Serum was then stored at 4°C for a second round of incubation. Mem-
branes were washed three times with TBST and then incubated in
stripping solution at 70°C. Filters were subsequently washed two times
in TBST and four times in TBS and then again blocked for 2 hours
with a blocking solution. Membranes were incubated with the stored
serum dilution overnight. Arrays were then washed three times with
TBST. Detection of bound autoantibodies was carried out by incuba-
tion with secondary antibody (1:1000 rabbit anti–human immuno-
globulins G and A and immunoglobulin M–Cy5 [H + L; Dianova,
Hamburg, Germany] in blocking solution). Finally, filters were washed
four times in TBST, two times in TBS and subsequently dried over-
night. Signals were detected by scanning with Typhoon 9410 scanner
(GE Healthcare, Uppsala, Sweden).
Image Analysis and Statistics
Spot intensity was computed by a novel computer-aided image
analysis procedure. In brief, macroarray was divided in target areas that
contained all pixels of a single protein spot. Subsequently, the target area
was clustered in foreground and background pixels. By applying the so-
called black top-hat operator known from the image analysis field, the
dark foreground spots were extracted from the pale background. Finally,
mean intensity of all foreground pixels was calculated, and the average
over the intensities of both replicates for each clone was computed.
We carried out standard quantile normalization to minimize array-
to-array variations. Because our image analysis method also detects
not available spots, we were able to exclude spots that show more than
10 not-available spots on all arrays. The remaining 1417 clones were
used for the classifications of glioma sera versus healthy sera, WHO IV
glioma sera versus healthy sera andWHO IV glioma sera versusWHO II/
III sera by a linear support vector machine. Altogether, 100 repetitions
of a standard 10-fold cross-validation were performed, and mean sen-
sitivity, specificity, and accuracy for the three classification tasks was cal-
culated. To test for overtraining, we performed 100 classification runs
with randomly permuted class labels.
As a measure of the information content of single antigens for their
ability to differentiate glioma sera versus healthy sera, WHO IV glioma
sera versus healthy sera, and WHO IV glioma sera versus WHO II/III
sera, the area under the receiver operator characteristic curve (ROC)
value (AUC) was computed. The ROC curve is specificity as function
of 1 − sensitivity. For each antigen, all normalized intensity values in
glioma and healthy sera were used as thresholds to discriminate glioma
sera from the healthy controls. For all these thresholds, glioma sera with
an intensity value above the threshold were considered as true-positive
(TP) and glioma sera with an intensity value below the threshold were
Table 1. Mean Age and Sex of the Considered Patient and Control Groups.
WHO n Mean Age Range
Glioma All grades All 57 44.3 4-78
Male 36 46.6 13-78
Female 21 40.4 4-75
WHO II/III All 22 39.5 16-71
Male 11 43.1 16-71
Female 11 35.8 22-53
WHO IV All 28 52.7 15-78
Male 21 50.8 15-78
Female 7 58.3 35-75
Healthy All 60 38.2 20-61
Male 41 38.2 20-61
Female 19 38.2 22-53
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considered as false-negative (FN). Accordingly, healthy sera with inten-
sity value below the threshold were considered as true-negative (TN)
and healthy sera with intensity value above the threshold were consid-
ered as false-positive (FP). Subsequently, sensitivity [TP / (TP + FN)]
and specificity [TN / (TN + FP)] of all thresholds were used to cal-
culate ROC curve and AUC value of the considered antigen. If in-
tensity values of the considered antigen in glioma sera are generally
higher than in healthy sera, AUC values range from 0 to 0.5. AUC
values ranging from 0.5 to 1 confer to a higher mean intensity of the
antigen in healthy sera compared with glioma sera. We considered anti-
gens with AUC values below 0.3 or above 0.7 as informative for the
given classification. Finally, we computed the frequency of seroreactivity
against the antigens in the considered groups by using a threshold of
50 for positive seroreactivity.
Results
Classification of Glioma Sera Using Protein
Macroarray Screening
We screened 57 glioma and 60 healthy sera for autoantibodies against
1827 E. coli expressed clones, including 509 in-frame peptide se-
quences. Signal intensity was measured by a novel automated proce-
dure as detailed in the Materials and Methods section. After quantile
normalization, 410 clones were excluded from further considerations
because these spots were labeled not available in more than 10 screened
sera by the image analysis procedure. By a linear support vector machine
approach, we discriminated glioma sera versus healthy sera, WHO IV
glioma versus healthy sera, and WHO IV glioma sera versus WHO II/
III glioma sera and calculated mean specificity, sensitivity, and accuracy
of 100 repetitive classifications (Table 2). Thereby we could differenti-
ate glioma sera from sera of the healthy control group with a specificity
of 90.28% (95% confidence interval [CI], 89.90%-90.67%), a sen-
sitivity of 87.31% (95% CI, 86.82%-87.81%), and an accuracy of
88.84% (95%CI, 88.50%-89.17%). We were also able to differentiate
WHO IV glioma sera from healthy sera with a specificity of 98.45%
(95% CI, 98.22%-98.68%), a sensitivity of 80.93% (95% CI,
80.48%-81.37%), and an accuracy of 92.88% (95% CI, 92.66%-
93.09%). The separation of WHO IV glioma sera from WHO II/III
glioma sera only yielded a specificity of 42.86% (95% CI, 42.06%-
43.67%), a sensitivity of 57.00% (95% CI, 56.01%-57.99%), and
an accuracy of 50.78% (95%CI, 50.13%-51.43%), which means that,
with this set of tumor-associated antigens, a separation of these two
groups is not possible. Likewise, separation of WHO II glioma versus
healthy, WHO III glioma versus healthy, and WHO IV glioma versus
WHO II glioma was not possible (data not shown). As controls, we
performed a random, stratified permutation of class labels for the all
classifications. In this control, we obtained mean results for specificity,
sensitivity, and accuracy of approximately 50%.
Information Content of Antigens
To rank the antigens according to their information content for
the four classification tasks, we computed the AUC value for each clone
as detailed in the Materials and Methods section. Table 3 provides an
overview on the distribution of AUC values among the clones. Most
antigens provided no or little information for the classification tasks:
only 3% to 7% of the clones yielded AUC values of above 0.7 or below
0.3, which represents the AUC range in that an antigen is considered
informative. Altogether, 46 clones including 16 in-frame clones were
considered informative for the classification of glioma sera versus
healthy sera. For the separation of WHO IV glioma versus healthy sera,
91 clones including 26 in-frame clones were considered informative.
Table 4 lists these in-frame clones with their corresponding AUC val-
ues. The best-suited in-frame clone for the classification glioma sera
versus healthy sera corresponded to the vimentin gene (VIM ) with an
AUC of 0.225 (Figure 1). Interestingly, the same clone was also best
suited for the classification of WHO IV glioma sera versus healthy sera
Table 2. Mean Values of Specificity, Sensitivity, and Accuracy for the Classifications of Glioma versus Healthy Controls, WHO IV Glioma versus Healthy Controls, and WHO IV Glioma versus
WHO II/III Glioma.
Classification Specificity Sensitivity Accuracy
Glioma vs healthy 90.28 (89.90-90.67) 87.31 (86.82-87.81) 88.84 (88.50-89.17)
Random 51.03 (49.82-52.25) 47.47 (46.06-48.88) 49.30 (48.14-50.45)
WHO IV glioma vs healthy 98.45 (98.22-98.68) 80.93 (80.48-81.37) 92.88 (92.66-93.09)
Random 73.52 (72.40-74.64) 23.96 (22.19-25.73) 57.75 (56.67-58.83)
WHO IV glioma vs WHO II/III glioma 42.86 (42.06-43.67) 57.00 (56.01-57.99) 50.78 (50.13-51.43)
Random 41.36 (39.19-43.54) 56.79 (55.24-58.33) 50.00 (48.45-51.55)
Values were calculated in 100 cross-validated classification runs. As control, 100 classification runs were done with randomly permutated class labels. CIs are given in parentheses.
Table 3. Distribution of Clones According to the AUC Values That Were Determined for the Classification of Glioma versus Healthy Controls and WHO IV Glioma versus Healthy Controls.
AUC Value Glioma vs Healthy WHO IV Glioma vs Healthy WHO IV Glioma vs WHO II/III Glioma
No. All Clones No. In-frame Clones No. All Clones No. In-frame Clones No. All Clones No. In-frame Clones
0.0-0.1 0 0 0 0 0 0
0.1-0.2 0 0 4 3 0 0
0.2-0.3 38 16 55 22 2 0
0.3-0.4 219 69 218 71 125 41
0.4-0.5 513 166 455 149 509 155
0.5-0.6 506 140 452 113 555 143
0.6-0.7 133 0 201 32 216 51
0.7-0.8 8 0 30 1 10 1
0.8-0.9 0 0 2 0 0 0
Number of all clones and number of in-frame clones is given for each AUC interval. In-frame clones with AUC values lower than 0.3 or above 0.7 were considered informative for a classification task (bold).
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with an AUC value of 0.173. Altogether, 16 clones were informa-
tive for both the classification of glioma sera versus healthy sera and
of WHO IV glioma sera versus healthy sera. These clones include di-
hydrolipoyl dehydrogenase (DLD), centromere protein B (CENPB),
and 40S ribosomal protein S2 (RPS2). Other informative clones for
the discrimination of WHO IV glioma sera versus healthy include glial
fibrillary acidic protein (GFAP), inhibitor of growth family member 4
(ING4 ), and pleiotrophin (PTN ).
Frequency of Seroreactivity against the Antigens
To assess a frequency of seroreactivity for the examined antigens,
we considered a serum as positive for autoantibodies against an anti-
gen if the intensity value of the corresponding spot is above 50. Sub-
sequently, the frequency of seroreactivity against every antigen after the
normalization procedure was computed as mean reactivity in glioma
and healthy controls. Table 5 shows the distribution of the remaining
1417 antigenic clones including the 391 in-frame clones in the given
frequency intervals. There are 23 clones including 4 in-frame clones
reacting with more than 60% of glioma sera. Forty-three clones in-
cluding 7 in-frame clones reacted with more than 60% of healthy sera.
Because many antigens react with high frequencies in glioma and
healthy sera, we computed the number of antigens reacting twice as
frequent with glioma sera than with healthy sera. Thereby we obtained
47 clones including 7 in-frame clones that react at least twice as fre-
quent with glioma sera than with healthy sera and, furthermore, that
react with at least 20% of glioma sera (Table 6). The clone with the
highest frequency in glioma represented the gene nonhomologous
end-joining factor 1 (NHEJ1) reacting with 36.8% of glioma sera
but also with 18.3% of healthy sera. Notably, two of the clones, namely
tetratricopeptide repeat protein 3 (TTC3) and amyloid β A4 precursor
protein-binding family B member 1 (APBB1), react at least twice as
often with glioma sera than with healthy sera and, furthermore, provide
good information for the discrimination of WHO IV glioma sera versus
healthy sera. TTC3 provided an AUC value of 0.254 for the discrimi-
nation and was reactive with 26.3% of glioma sera and 6.7% of healthy
sera. APBB1 yielded an AUC value of 0.294 and reacted with 21.1% of
glioma sera and 10.0% of healthy sera.
Discussion
The usefulness of autoantibody signatures for the detection of cancer
has been shown by our group and others for multiple cancer types in-
cluding meningioma, prostate, lung, and ovarian cancers [5–19]. We
could demonstrate a complex seroreactivity pattern in meningioma,
and by using this pattern, we could differentiate meningioma from
healthy controls with a specificity of 96.2%, a sensitivity of 84.5%,
and an accuracy of 90.3% [10,11]. Wang et al. [5] separated sera of
prostate cancer patients from sera of a control group with a specificity of
88.2% and a sensitivity of 81.6%. Zhong et al. [6] were able to dis-
criminate sera of patients with non–small cell lung cancer from normal
sera with a specificity of 95% and a sensitivity of 90%. A study on lung
adenocarcinoma patients yielded a specificity of 86% and a sensitivity of
85% [7]. Chatterjee et al. [8] could differentiate ovarian cancer with
an average specificity of 90% and a sensitivity of 32%, whereas Erkanli
et al. [9] classified sera of epithelial ovarian cancer patients with an AUC
value of 0.86 without noticing sensitivity or specificity.
Although the knowledge about a humoral antitumor immune re-
action in glioma in general is several decades old, the more detailed
view on the involved antigens and the concept of using this response
to diagnose glioma evolved over the last decade [21–23]. After the de-
velopment of new methods to identify tumor-associated antigens in
greater number, such as SEREX or T7 phage display, the number of
glioma-associated antigens also grew [24,25]. Until now, 61 glioma-
associated antigens are listed in the Cancer Immunome Database [26],
and several more are published by our group and others [12,27–29].
After identifying a set of glioma-associated antigens, we were the first
to screen a large number of glioma sera and various controls including
Table 4. AUC Value of Highly Informative Antigens for the Classification of Glioma Sera versus Healthy Controls and of WHO IV Glioma Sera versus Healthy Controls.
Clone ID Ensemble ID Gene Name AUC Glioma vs Healthy AUC WHO IV Glioma vs Healthy Known Antigen
B17512 ENSG00000026025 VIM 0.225 0.173 +
M19590 ENSG00000140988 RPS2 0.226 0.188 +
K19595 ENSG00000142937 RPS8 0.232 0.175
J15577 ENSG00000026025 VIM 0.247 0.261 +
F16565 ENSG00000083812 ZNF324 0.248 0.275
G19583 ENSG00000122406 RPL5 0.251 0.261
H18530 ENSG00000091140 DLD 0.258 0.263
E14506 ENSG00000198708 LOC388720 0.265 0.236
G20580 ENSG00000105220 GPI 0.266 0.255
G13583 ENSG00000167588 GPD1 0.282 0.235
D14506 ENSG00000198708 LOC388720 0.287 0.279
O03589 ENSG00000140988 RPS2 0.289 0.242 +
C09514 ENSG00000170759 KIF5B 0.291 0.289
H22512 ENSG00000125817 CENPB 0.292 0.288 +
H23512 ENSG00000180626 ZNF594 0.293 0.282 +
F10567 ENSG00000005194 CIAPIN1 0.293 0.285
K19538 ENSG00000182670 TTC3 0.304 0.254 +
I17585 ENSG00000127903 FLJ12955 0.314 0.266
D18552 ENSG00000153317 DDEF1 0.306 0.279
O11577 ENSG00000105894 PTN 0.308 0.279
H21512 ENSG00000131095 GFAP 0.325 0.277 +
F12523 ENSG00000075340 ADD2 0.349 0.279
M18573 ENSG00000111653 ING4 0.309 0.288
O20573 ENSG00000151914 DST 0.316 0.292 +
M15565 ENSG00000166313 APBB1 0.332 0.294
B09544 ENSG00000106244 PDAP1 0.664 0.714 +
+ indicates that antigen is deposited in the Cancer Immunome Database.
* Numbers in bold indicate informative antigens.
1386 Novel Markers in Glioma Ludwig et al. Neoplasia Vol. 11, No. 12, 2009
other tumor and nontumor pathologic lesions of the brain and to use the
detected seroreactivity patterns for glioma differentiation [12]. By using
a SEREX-derived method, we were able to discriminate glioma sera
from healthy controls with a specificity of 87.8% and sensitivity of
85.2% and an accuracy of 86.5%, and furthermore, we could differenti-
ate glioma sera from controls with other pathologic lesions of the brain
yielding a specificity of 86.1% and a sensitivity of 85.2% and an accuracy
of 85.8% [12].
The two major goals of the present study were to identify novel
immunogenic antigens in glioma and to test their value for the differen-
tiation of glioma patients from healthy controls. To achieve these aims,
we screened a novel array encompassing 1827 disease-related immuno-
genic clones with sera of glioma patients and healthy controls and
evaluated the results with state of the art statistical learning methods.
Thereby we were able to discriminate glioma sera from healthy controls
with a specificity of 90.28%, a sensitivity of 87.31%, and an accuracy of
Table 5. Distribution of Clones According to the Seroreactivity Frequency Determined for Glioma and for Healthy Controls (First and Second Column).
Frequency Range Glioma Healthy Glioma (Twice)
No. All Clones No. In-frame Clones No. All Clones No. In-frame Clones No. All Clones No. In-frame Clones
0% 51 17 176 62 — —
0-10% 536 176 552 169 152 91
10-20% 444 117 305 78 109 49
20-30% 187 40 163 36 34 5
30-40% 100 20 93 22 7 2
40-50% 54 14 55 8 3 0
50-60% 22 3 30 9 2 0
60-70% 16 4 27 5 1 0
70-80% 4 0 11 2 0 0
80-90% 3 0 4 0 0 0
90-100% 0 0 1 0 0 0
The third column lists clones that react at least twice as often with glioma sera than with healthy control sera. Number of all clones and number of in-frame clones are given for each frequency interval.
Figure 1. Seroreactivity against the clone representing VIM. The graphs show the intensity values of seroreactivity (y-axis) in the tested
sera (x-axis). Mean seroreactivity value is indicated as horizontal line. (A) Intensity values of seroreactivity against clone VIM are provided
for healthy controls (empty circle) and for glioma sera (full circle). (B) Intensity values of seroreactivity against clone VIM are provided for
healthy controls (empty circle) and WHO IV glioma sera (full circle).
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88.84%. In comparison to our SEREX-derived classifier, we could im-
prove specificity and accuracy of the classification of glioma sera versus
healthy controls by using this extended set of immunogenic clones
[12]. Furthermore, we could even differentiate WHO IV glioma sera
from healthy sera with a specificity of 98.45%, a sensitivity of 80.93%,
and an accuracy of 92.88%.
To assess the value of single antigens for a classification task, we
ranked the antigens according to their AUC value. Antigens best suited
to differentiate glioma sera or WHO IV glioma sera from healthy con-
trols showed AUC values of 0 to 0.3 or 0.7 to 1. This led to the iden-
tification of several novel antigens previously not associated with glioma
as well as antigens already known in context of glioma. GFAP, ING4,
PTN, and TTC3 offered a high discrimination power for the classifica-
tion of WHO IV glioma sera versus healthy sera. GFAP and TTC3 have
been deposited at the Cancer Immunome Database as autoantigens de-
tected with glioma serum [20]. ING4 has already been identified as a
glioma-associated antigen in our previous study that used the classic
SEREX approach [12]. GFAP has been found to be strongly expressed
in WHO IV glioma [30]. The level of expression of PTN was associ-
ated with histopathologic grade in astrocytoma [31].
The intermediate filament protein vimentin (VIM) was best suited for
the classification of glioma sera versus healthy sera and of glioblastoma
sera versus healthy sera. In normal brain, VIM expression is specific for
cells of glial origin. Accordingly, VIM is strongly expressed in glioma
especially in glioblastoma and is associated with enhanced motility and
invasive growth in astrocytoma [30,32]. Furthermore, VIM is expressed
on the surface of apoptotic cells and has been shown to induce the pro-
duction of autoantibodies [33,34]. Autoantibodies against VIM have
previously been identified in pancreatic cancer and rheumatoid arthritis
[35,36]. Although VIM is strongly expressed in glioma, its expression
in normal glial cells remains a major obstacle for the development of a
vimentin-based therapy approach.
To achieve a curative treatment of glioma, future clinical settings
will be focused on two aspects: the removal of the primary tumor and
the deletion of the diffusely distributed glioma cells in the surrounding
brain parenchyma. Whereas elimination of the primary tumor mass
will include conventional radiotherapy and resection, elimination of
single tumor cells within the brain will include conventional chemo-
therapy and newly developed immune-based therapy strategies as gene
therapy and vaccination. Although there are many clinical trails regard-
ing treatment of malignant glioma or glioblastoma, most of them are
focused on different combinations of chemotherapeutic agents with ra-
diation therapy and resection. Only a few immune therapeutic strate-
gies have reached phase 1 or 2 clinical trails. These include vaccination
of the patients with tumor lysate–pulsed, autologous dendritic cells or
vaccination with tumor-isolated proteins or with synthetic peptides tar-
geting epidermal growth factor receptor variant III [37–39]. Although
some of these studies show promising results, for further improvement
of immune therapy–based treatment in glioma patients, there is a need
for identification of more target proteins. Autoantibody signatures gen-
erated from an extended set of autoantigens in glioma can prove useful
for glioma therapy in two ways, namely early diagnosis and personalized
therapy. Although there is no evidence that early diagnosis yields to an
improved clinical outcome in patients with malignant glioma, this
evidence was found for several other cancers such as prostate or colon
cancer [40,41]. It has also been shown that autoantibodies can be de-
tected years before onset of the disease, for example, against the tumor
protein p53 in lung cancer [42]. In addition, glioma-associated anti-
gens identified by the autoantibody signatures may offer themselves
as possible future targets for an immune-based therapy in glioma.
The determination of autoantibody signatures for each patient and
the identification of specific targets may contribute to a personalized
medicine for glioma patients.
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